References
- Lew DP, Waldvogel FA. Osteomyelitis. N Engl J Med 1997; 336: 999–1007.
- Wimer SM, Schoonover L, Garrison MW. Levofloxacin: a therapeutic review. Clin Ther 1998; 20, 1049–70.
- Rimmele T, BoseIli E, Breilh D, et al. Diffusion of lev-ofloxacin into bone and synovial tissues. J Antimicrob Chemother 2004; 53, 533–5.
- Oberdorfer K, Swoboda S, Hamann A et al. Tissue and serum levofloxacin concentrations in diabetic foot infection patients. J Antimicrob Chemother 2004; 54: 836–9.
- Chow AT, Chen A, Lattime H et al. Penetration of lev-ofloxacin into skin tissue after oral administration of multiple 750 mg once-daily doses. J Clin Pharmacol Ther 2002; 27: 143–50.
- Preston SL, Drusano GL, Berman AL et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998; 279: 125–9.
- Wright DH, Brown GH, Peterson ML et al. Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother 2000; 46: 669–83.
- Norden CW. Experimental chronic staphylococcal osteomyelitis in rabbits: treatment with rifampin alone and in combination with other antimicrobial agents. Rev Infect Dis 1983; 5 Suppl 1: 491–94.
- Wehrli W. Rifampin: mechanisms of action and resis-tance. Rev Infect Dis 1983; 5 Suppl 1: 407–11.
- Zavasky DM, Sande MA. Reconsideration of rifampin: a unique drug for a unique infection. JAMA 1998; 279: 1575–7.
- Shirtliff ME, Calhoun JH, Mader JT. Comparative eval-uation of oral levofloxacin and parenteral nafcillin in the treat-ment of experimental methicillin-susceptible Staphylococcus aureus osteomyelitis in rabbits. J Antimicrob Chemother 2001; 48, 253–8
- Murillo O, Domenech A, Garcia A, Tubau F, Cabellos C, Gudiol F, Ariza J. Efficacy of high-doses of levofloxacin in experimental foreign-body infection by methicillin-susceptible S. aureus. Antimicrob Agents Chemother 2006; 50: 4011-7.
- Zimmerli W, Trampuz A, Ochsner PE. Prosthetic joint infections. N Engl J Med 2004; 351: 1645–54.
- Viale P, Pea F, Scudeller L et al. Pharmacokinetic and pharmacodynamic aspects of high dose oral levofloxacin ther-apy for bone infections. Clin Microb Infect 2005; 11 Suppl2: 653.
- Greenberg RN, Newman MT, Shariaty S et al. Ciprofloxacin, lomefloxacin, or levofloxacin as treatment for chronic osteomyelitis. Antimicrob Agents Chemother 2000; 44: 164–6.
- Azanza JR, Cardenas E, Munoz MJ et al. Clinical expe-rience with long-term treatment of osteoarticular infections. Rev Med Univ Navarra 2002; 46: 23–7.
- Ortega M, Soriano A, Garcia S, et al. Tolerability and safety of levofloxacin long-term treatment. Rev Esp Quimioter 2000; 13 :263–6.
- Zimmerli W, Widmer AF, Blatter M, et al. Role of rifampin for treatment of orthopedic implant-related staphylo-coccal infections. JAMA 1998; 279: 1537–41.
- Rissing JP. Antimicrobial therapy for chronic osteomyelitis in adults: role of the quinolones. Clin Infect Dis 1997; 25: 1327–33.
- Kang SL, Ryback MJ, McGrath BJ et al. Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and-resistant Staphylococcus aureus in an in vitro infection model. Antimicrob Agents Chemother 1994; 38: 2702–9.
- Humbert G., Brumpt I, Montay G, Le Liboux A, Sorsa-Lebas F, Moore N. Influence of rifampin on the pharmacoki-netics of pefloxacin. Clin Pharmacol Ther. 1991; 50: 682–7.
- Chow AT, Fowler C, Williams RR et al. Safety and pharmacokinetics of multiple 750-milligram doses of intra-venous levofloxacin in healthy volunteers. Antimicrob Agents Chemother 2001; 45: 2122–5.
- Chien S-C, Wong FA, Fowler CL et al. Double-bind evaluation of the safety and pharmacokinetics of multiple once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers. Antimicrob Agents Chemother 1998 ; 42: 885–8.
- Graham DR, Talan DA, Nichols RL et al. Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial. Clin Infect Dis 2002; 35: 381–9.